Skip to Content

Skyrizi (risankizumab) Disease Interactions

There are 4 disease interactions with Skyrizi (risankizumab):


Risankizumab (applies to Skyrizi) hepatic/renal

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab. Caution is advised.


Risankizumab (applies to Skyrizi) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Risankizumab may increase the risk of infections., and treatment with this medication should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing risankizumab. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer risankizumab until the infection resolves.


Risankizumab (applies to Skyrizi) TB infection

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Tuberculosis -- Active, Tuberculosis -- Latent

Patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment with risankizumab. Consider anti-TB therapy prior to initiating treatment in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after risankizumab treatment. Do not administer this medication to patients with active TB.


Risankizumab (applies to Skyrizi) vaccinations

Moderate Potential Hazard, Moderate plausibility.

Prior to initiating therapy with risankizumab, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with risankizumab. No data are available on the response to live or inactive vaccines.

Skyrizi (risankizumab) drug interactions

There are 121 drug interactions with Skyrizi (risankizumab)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.